UPA medicine for uterine fibroids remains available in a number of Latin American and CIS countries
December 2024. The marketing authorisation for Esmya was withdrawn in July from the European Economic Area and Belarus, Moldova, Serbia, Ukraine and the United Kingdom, at the request of the marketing-authorisation holder. (See announcement on the European’s Medicines Agency’s website here). The withdrawal was due to commercial reasons and there is no change in the safety…